Compounded semaglutide associated with at least 10 deaths, Novo Nordisk …
Nov 6, 2024 · Novo Nordisk said the data on 10 deaths and more than 100 hospitalizations came from the US Food and Drug Administration’s adverse event reporting database for semaglutide; the FDA warns that ...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
Nov 6, 2024 · Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in ...
Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance. 📺 24/7 Chicago news stream: Watch ...
Novo Nordisk Reports Headline Results From Part 1 Of ESSENCE …
Nov 1, 2024 · (RTTNews) - Novo Nordisk (NVO) announced the headline results from part 1 of the ongoing ESSENCE trial, a phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic...
Latest news - Novo Nordisk
21 October 2024. Novo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial. Read more.
Novo Nordisk's Ozempic, Wegovy now available after shortages
Oct 30, 2024 · All doses of Novo Nordisk ’s highly popular weight loss injection Wegovy and diabetes drug Ozempic are now available in the U.S., according to an update on the U.S. Food and Drug...
Novo Nordisk CEO testifies at Senate over weight loss drug prices
Sep 24, 2024 · Novo Nordisk ’s top executive faced a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars...
Novo Nordisk Q2 2024 results - CNBC
Aug 7, 2024 · Novo Nordisk is facing increasing competition in the weight loss space, both from smaller companies and from pharmaceutical giants such as Roche, which last month shared promising early-stage...
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
Jan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
Apr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.